Disappointing Trial Results For Adams Respiratory
Adams Respiratory Therapeutics Inc. (ARXT) reported disappointing midstage results for its chronic bronchitis treatment erdosteine and forecast third quarter as well as full year sales below expectations. The stock price plummeted $9.45 to close at $28.22.
0 Comments:
Post a Comment
<< Home